The Experts below are selected from a list of 1059 Experts worldwide ranked by ideXlab platform

S.-d. Xiao - One of the best experts on this subject based on the ideXlab platform.

  • One‐week regimens containing Ranitidine Bismuth Citrate, furazolidone and either amoxicillin or tetracycline effectively eradicate Helicobacter pylori: a multicentre, randomized, double‐blind study
    Alimentary pharmacology & therapeutics, 2001
    Co-Authors: D.-z. Zhang, X.-c. Fang, S.-d. Xiao
    Abstract:

    Background: The metronidazole resistance of Helicobacter pylori strains has increased rapidly. Aim: To evaluate the efficacy and safety of new 1-week regimens containing Ranitidine Bismuth Citrate, furazolidone and either amoxicillin or tetracycline. Methods: One hundred and twenty patients with H. pylori-positive inactive duodenal ulcer or non-ulcer dyspepsia diagnosed by endoscopy were recruited randomly to receive one of two regimens for 7 days: Ranitidine Bismuth Citrate, 350 mg b.d., furazolidone, 100 mg b.d., and either amoxicillin, 1000 mg b.d. (n=60), or tetracycline, 500 mg b.d. (n=60). H. pylori infection was identified by rapid urease testing and histology. 13C-Urea breath test was performed to evaluate the cure of H. pylori infection at least 4 weeks after completion of triple therapy. Results: The eradication rates of H. pylori by Ranitidine Bismuth Citrate–furazolidone–amoxicillin and Ranitidine Bismuth Citrate–furazolidone–tetracycline regimens were 82% and 85% (P > 0.05), respectively, by intention-to-treat analysis, and 85% and 91% (P > 0.05), respectively, by per protocol analysis. Adverse effects were mild in both Ranitidine Bismuth Citrate–furazolidone–amoxicillin and Ranitidine Bismuth Citrate–furazolidone–tetracycline groups. Conclusions: One-week regimens containing Ranitidine Bismuth Citrate, furazolidone and amoxicillin or tetracycline are well tolerated and effective for the eradication of H. pylori.

  • one week regimens containing Ranitidine Bismuth Citrate furazolidone and either amoxicillin or tetracycline effectively eradicate helicobacter pylori a multicentre randomized double blind study
    Alimentary Pharmacology & Therapeutics, 2001
    Co-Authors: D.-z. Zhang, X.-c. Fang, S.-d. Xiao
    Abstract:

    Background: The metronidazole resistance of Helicobacter pylori strains has increased rapidly. Aim: To evaluate the efficacy and safety of new 1-week regimens containing Ranitidine Bismuth Citrate, furazolidone and either amoxicillin or tetracycline. Methods: One hundred and twenty patients with H. pylori-positive inactive duodenal ulcer or non-ulcer dyspepsia diagnosed by endoscopy were recruited randomly to receive one of two regimens for 7 days: Ranitidine Bismuth Citrate, 350 mg b.d., furazolidone, 100 mg b.d., and either amoxicillin, 1000 mg b.d. (n=60), or tetracycline, 500 mg b.d. (n=60). H. pylori infection was identified by rapid urease testing and histology. 13C-Urea breath test was performed to evaluate the cure of H. pylori infection at least 4 weeks after completion of triple therapy. Results: The eradication rates of H. pylori by Ranitidine Bismuth Citrate–furazolidone–amoxicillin and Ranitidine Bismuth Citrate–furazolidone–tetracycline regimens were 82% and 85% (P > 0.05), respectively, by intention-to-treat analysis, and 85% and 91% (P > 0.05), respectively, by per protocol analysis. Adverse effects were mild in both Ranitidine Bismuth Citrate–furazolidone–amoxicillin and Ranitidine Bismuth Citrate–furazolidone–tetracycline groups. Conclusions: One-week regimens containing Ranitidine Bismuth Citrate, furazolidone and amoxicillin or tetracycline are well tolerated and effective for the eradication of H. pylori.

D.-z. Zhang - One of the best experts on this subject based on the ideXlab platform.

  • One‐week regimens containing Ranitidine Bismuth Citrate, furazolidone and either amoxicillin or tetracycline effectively eradicate Helicobacter pylori: a multicentre, randomized, double‐blind study
    Alimentary pharmacology & therapeutics, 2001
    Co-Authors: D.-z. Zhang, X.-c. Fang, S.-d. Xiao
    Abstract:

    Background: The metronidazole resistance of Helicobacter pylori strains has increased rapidly. Aim: To evaluate the efficacy and safety of new 1-week regimens containing Ranitidine Bismuth Citrate, furazolidone and either amoxicillin or tetracycline. Methods: One hundred and twenty patients with H. pylori-positive inactive duodenal ulcer or non-ulcer dyspepsia diagnosed by endoscopy were recruited randomly to receive one of two regimens for 7 days: Ranitidine Bismuth Citrate, 350 mg b.d., furazolidone, 100 mg b.d., and either amoxicillin, 1000 mg b.d. (n=60), or tetracycline, 500 mg b.d. (n=60). H. pylori infection was identified by rapid urease testing and histology. 13C-Urea breath test was performed to evaluate the cure of H. pylori infection at least 4 weeks after completion of triple therapy. Results: The eradication rates of H. pylori by Ranitidine Bismuth Citrate–furazolidone–amoxicillin and Ranitidine Bismuth Citrate–furazolidone–tetracycline regimens were 82% and 85% (P > 0.05), respectively, by intention-to-treat analysis, and 85% and 91% (P > 0.05), respectively, by per protocol analysis. Adverse effects were mild in both Ranitidine Bismuth Citrate–furazolidone–amoxicillin and Ranitidine Bismuth Citrate–furazolidone–tetracycline groups. Conclusions: One-week regimens containing Ranitidine Bismuth Citrate, furazolidone and amoxicillin or tetracycline are well tolerated and effective for the eradication of H. pylori.

  • one week regimens containing Ranitidine Bismuth Citrate furazolidone and either amoxicillin or tetracycline effectively eradicate helicobacter pylori a multicentre randomized double blind study
    Alimentary Pharmacology & Therapeutics, 2001
    Co-Authors: D.-z. Zhang, X.-c. Fang, S.-d. Xiao
    Abstract:

    Background: The metronidazole resistance of Helicobacter pylori strains has increased rapidly. Aim: To evaluate the efficacy and safety of new 1-week regimens containing Ranitidine Bismuth Citrate, furazolidone and either amoxicillin or tetracycline. Methods: One hundred and twenty patients with H. pylori-positive inactive duodenal ulcer or non-ulcer dyspepsia diagnosed by endoscopy were recruited randomly to receive one of two regimens for 7 days: Ranitidine Bismuth Citrate, 350 mg b.d., furazolidone, 100 mg b.d., and either amoxicillin, 1000 mg b.d. (n=60), or tetracycline, 500 mg b.d. (n=60). H. pylori infection was identified by rapid urease testing and histology. 13C-Urea breath test was performed to evaluate the cure of H. pylori infection at least 4 weeks after completion of triple therapy. Results: The eradication rates of H. pylori by Ranitidine Bismuth Citrate–furazolidone–amoxicillin and Ranitidine Bismuth Citrate–furazolidone–tetracycline regimens were 82% and 85% (P > 0.05), respectively, by intention-to-treat analysis, and 85% and 91% (P > 0.05), respectively, by per protocol analysis. Adverse effects were mild in both Ranitidine Bismuth Citrate–furazolidone–amoxicillin and Ranitidine Bismuth Citrate–furazolidone–tetracycline groups. Conclusions: One-week regimens containing Ranitidine Bismuth Citrate, furazolidone and amoxicillin or tetracycline are well tolerated and effective for the eradication of H. pylori.

Jan H. Kleibeuker - One of the best experts on this subject based on the ideXlab platform.

  • The influence of metronidazole resistance on the efficacy of Ranitidine Bismuth Citrate triple therapy regimens for Helicobacter pylori infection
    1999
    Co-Authors: Ej ,van Der Wouden, J. C. Thijs, Aa ,van Zwet, Kooy A, Jan H. Kleibeuker
    Abstract:

    Aim: To assess the influence of metronidazole resistance on the efficacy of Ranitidine Bismuth Citrate-based triple therapy regimens in two consecutive studies. Methods: In the first study, patients with a culture-proven Helicobacter pylori infection were treated with Ranitidine Bismuth Citrate 400 mg, metronidazole 500 mg, and clarithromycin 500 mg, all twice dairy for 1 week (RMC). In the second study, amoxycillin 1000 mg was substituted for clarithromycin (RMA). Susceptibility testing for metronidazole was performed with the E-test. Follow-up endoscopy was performed after greater than or equal to 4 weeks. Antral biopsy samples were taken for histology and urease test, and culture and corpus samples for histology and culture. Results: 112 patients, 53 males, age 55 +/- 14 years (39 duodenal ulcer, 7 gastric ulcer and 66 gastritis) were treated with RMC, and 89 patients, 52 males, age 58 +/- 15 years (23 duodenal ulcer, 7 gastric ulcer and 59 gastritis) were treated with RMA. For RMC, intention-to-treat eradication results were 98% (59/60, 95% CI: 91-100%) and 95% (20/21, 95% CI: 76-100%) for metronidazoIe susceptible and resistant strains, respectively (P = 0.45). For RMA these figures were 87% (53/61, 95% CT: 76-94%) for metronidazole susceptible strains and 22% (2/9, 95% CI: 3-60%) for resistant strains (P = 0.0001). Conclusion: Both regimens are effective in metronidazole susceptible strains. However, in contrast to the amoxycillin-containing regimen, that containing clarithromycin is also effective in resistant strains

  • The influence of metronidazole resistance on the efficacy of Ranitidine Bismuth Citrate triple therapy regimens for Helicobacter pylori infection
    Alimentary pharmacology & therapeutics, 1999
    Co-Authors: Ej Van Der Wouden, J. C. Thijs, Aa Van Zwet, A Kooy, Jan H. Kleibeuker
    Abstract:

    Aim : To assess the influence of metronidazole resistance on the efficacy of Ranitidine Bismuth Citrate-based triple therapy regimens in two consecutive studies. Methods : In the first study, patients with a culture-proven Helicobacter pylori infection were treated with Ranitidine Bismuth Citrate 400 mg, metronidazole 500 mg, and clarithromycin 500 mg, all twice daily for 1 week (RMC). In the second study, amoxycillin 1000 mg was substituted for clarithromycin (RMA). Susceptibility testing for metronidazole was performed with the E-test. Follow-up endoscopy was performed after ≥ 4 weeks. Antral biopsy samples were taken for histology and urease test, and culture and corpus samples for histology and culture. Results : 112 patients, 53 males, age 55 ± 14 years (39 duodenal ulcer, 7 gastric ulcer and 66 gastritis) were treated with RMC, and 89 patients, 52 males, age 58 ± 15 years (23 duodenal ulcer, 7 gastric ulcer and 59 gastritis) were treated with RMA. For RMC, intention-to-treat eradication results were 98% (59/60, 95% CI: 91–100%) and 95% (20/21, 95% CI: 76–100%) for metronidazole susceptible and resistant strains, respectively (P = 0.45). For RMA these figures were 87% (53/61, 95% CI: 76–94%) for metronidazole susceptible strains and 22% (2/9, 95% CI: 3–60%) for resistant strains (P = 0.0001). Conclusion : Both regimens are effective in metronidazole susceptible strains. However, in contrast to the amoxycillin-containing regimen, that containing clarithromycin is also effective in resistant strains.

  • One-Week Triple Therapy With Ranitidine Bismuth Citrate, Clarithromycin and Metronidazole Versus Two-Week Dual Therapy With Ranitidine Bismuth Citrate and Clarithromycin for Helicobacter pylori Infection: A Randomized, Clinical Trial
    The American journal of gastroenterology, 1998
    Co-Authors: Ej Van Der Wouden, J. C. Thijs, Aa Van Zwet, A Kooy, Jan H. Kleibeuker
    Abstract:

    One-Week Triple Therapy With Ranitidine Bismuth Citrate, Clarithromycin and Metronidazole Versus Two-Week Dual Therapy With Ranitidine Bismuth Citrate and Clarithromycin for Helicobacter pylori Infection: A Randomized, Clinical Trial

Mf Yuen - One of the best experts on this subject based on the ideXlab platform.

  • One-week Ranitidine Bismuth Citrate, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese.
    Alimentary pharmacology & therapeutics, 2002
    Co-Authors: W. K. Hung, Wai Man Wong, Grace Sau‐wai Wong, A. W. C. Yip, Ming-leung Szeto, Kam Chuen Lai, C. K. Chan, Hhx Xia, Mf Yuen
    Abstract:

    Summary Background : We have previously shown that Ranitidine Bismuth Citrate-based, clarithromycin-containing triple therapy achieves a higher eradication rate than proton pump inhibitor-based regimens in areas with a high prevalence of metronidazole resistance. Aim : To evaluate whether this higher efficacy of Ranitidine Bismuth Citrate over proton pump inhibitor can be extended to non-clarithromycin-containing regimens. Methods : Helicobacter pylori-positive dyspeptic patients were randomized to receive either Ranitidine Bismuth Citrate, 400 mg, amoxicillin, 1000 mg, and metronidazole, 400 mg, or omeprazole, 20 mg, amoxicillin, 1000 mg, and metronidazole, 400 mg, each given twice daily for 1 week. H. pylori eradication was confirmed by 13C-urea breath test 5 weeks later. The side-effects of the treatments were documented. Results : Two hundred and twenty-nine patients were eligible for analysis. By intention-to-treat and per protocol analysis, the eradication rates were 77% and 79%, respectively, in the Ranitidine Bismuth Citrate–amoxicillin–metronidazole group and 77% and 82%, respectively, in the omeprazole–amoxicillin–metronidazole group (P = 0.58 and P = 0.65). However, patients in the omeprazole–amoxicillin–metronidazole group reported a significantly higher incidence of minor side-effects when compared to those in the Ranitidine Bismuth Citrate–amoxicillin–metronidazole group (P = 0.001). Conclusions : Ranitidine Bismuth Citrate–amoxicillin–metronidazole was equally as effective as omeprazole–amoxicillin–metronidazole triple therapy, and may be considered as an alternative non-clarithromycin-based regimen in the Chinese population.

  • One-week Ranitidine Bismuth Citrate, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese
    'Wiley', 2002
    Co-Authors: Wong Bcy, W. K. Hung, Mf Yuen, Xia Hhx, Sk Lam, Wm Wong, Fung Fmy, Tong Tsm, Ho Vyk, Wong Gsw
    Abstract:

    Background: We have previously shown that Ranitidine Bismuth Citrate-based, clarithromycin-containing triple therapy achieves a higher eradication rate than proton pump inhibitor-based regimens in areas with a high prevalence of metronidazole resistance. Aim: To evaluate whether this higher efficacy of Ranitidine Bismuth Citrate over proton pump inhibitor can be extended to non-clarithromycin-containing regimens. Methods: Helicobacter pylori-positive dyspeptic patients were randomized to receive either Ranitidine Bismuth Citrate, 400 mg, amoxicillin, 1000 mg, and metronidazole, 400 mg, or omeprazole, 20 mg, amoxicillin, 1000 mg, and metronidazole, 400 mg, each given twice daily for 1 week, H, pylori eradication was confirmed by 13C-urea breath test 5 weeks later. The side-effects of the treatments were documented. Results: Two hundred and twenty-nine patients were eligible for analysis. By intention-to-treat and per protocol analysis, the eradication rates were 77% and 79%, respectively, in the Ranitidine Bismuth Citrate-amoxicillin-metronidazole group and 77% and 82%, respectively, in the omeprazole-amoxicillin-metronidazole group (P = 0.58 and P = 0.65). However, patients in the omeprazole-amoxicillin-metronidazole group reported a significantly higher incidence of minor side-effects when compared to those in the Ranitidine Bismuth Citrate-amoxicillin-metronidazole group (P = 0.001). Conclusions: Ranitidine Bismuth Citrate-amoxicillin-metronidazole was equally as effective as omeprazole-amoxicillin-metronidazole triple therapy, and may be considered as an alternative non-clarithromycin-based regimen in the Chinese population.link_to_subscribed_fulltex

  • One‐week Ranitidine Bismuth Citrate‐based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistance
    Alimentary pharmacology & therapeutics, 2001
    Co-Authors: Bcy Wong, Wai Man Wong, Kam Chuen Lai, W. H. Wang, F. M. Y. Fung, Kent-man Chu, S. T. Yuen, Suet Yi Leung, Mf Yuen
    Abstract:

    Aim: To compare 1-week Ranitidine Bismuth Citrate-based (RBC) triple therapy vs. omeprazole-based (O) triple therapy for the eradication of Helicobacter pylori infection in Hong Kong with high prevalence of metronidazole resistance. Methods: Patients with non-ulcer dyspepsia and H. pylori infection were randomized to receive either: (i) RBCCM: Ranitidine Bismuth Citrate (pylorid) 400 mg, clarithromycin 250 mg and metronidazole 400 mg; or (ii) OCM: omeprazole 20 mg, clarithromycin 250 mg and metronidazole 400 mg, each given twice daily for 1 week. Endoscopy (CLO test, histology and culture) and 13C-urea breath test were performed before randomization and 6 weeks after drug treatment. Results: A total of 180 patients were randomized. H. pylori eradication rates (intention-to-treat, n=180/per protocol, n=166) were 83%/92% for RBCCM and 66%/70% for OCM (P=0.01, intention-to-treat and P=0.001, per protocol, respectively). RBCCM treatment was unaffected by metronidazole susceptibility and achieved a significantly higher eradication rate in metronidazole-resistant cases (89%) than the OCM group (45%, P=0.0064). Conclusion: One-week Ranitidine Bismuth Citrate-based triple therapy is significantly better than omeprazole-based triple therapy for the eradication of H. pylori infection, especially in metronidazole-resistant cases. It is an effective regimen for the eradication of H. pylori infection in regions with a high prevalence of metronidazole resistance.

  • one week Ranitidine Bismuth Citrate based triple therapy for the eradication of helicobacter pylori in hong kong with high prevalence of metronidazole resistance
    Alimentary Pharmacology & Therapeutics, 2001
    Co-Authors: Bcy Wong, Kam Chuen Lai, Mf Yuen, Wm Wong, W. H. Wang, F. M. Y. Fung, Kent-man Chu, S. T. Yuen, Suet Yi Leung, George K K Lau
    Abstract:

    Aim: To compare 1-week Ranitidine Bismuth Citrate-based (RBC) triple therapy vs. omeprazole-based (O) triple therapy for the eradication of Helicobacter pylori infection in Hong Kong with high prevalence of metronidazole resistance. Methods: Patients with non-ulcer dyspepsia and H. pylori infection were randomized to receive either: (i) RBCCM: Ranitidine Bismuth Citrate (pylorid) 400 mg, clarithromycin 250 mg and metronidazole 400 mg; or (ii) OCM: omeprazole 20 mg, clarithromycin 250 mg and metronidazole 400 mg, each given twice daily for 1 week. Endoscopy (CLO test, histology and culture) and 13C-urea breath test were performed before randomization and 6 weeks after drug treatment. Results: A total of 180 patients were randomized. H. pylori eradication rates (intention-to-treat, n=180/per protocol, n=166) were 83%/92% for RBCCM and 66%/70% for OCM (P=0.01, intention-to-treat and P=0.001, per protocol, respectively). RBCCM treatment was unaffected by metronidazole susceptibility and achieved a significantly higher eradication rate in metronidazole-resistant cases (89%) than the OCM group (45%, P=0.0064). Conclusion: One-week Ranitidine Bismuth Citrate-based triple therapy is significantly better than omeprazole-based triple therapy for the eradication of H. pylori infection, especially in metronidazole-resistant cases. It is an effective regimen for the eradication of H. pylori infection in regions with a high prevalence of metronidazole resistance.

  • One-week Ranitidine Bismuth Citrate-based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistance
    'Wiley', 2001
    Co-Authors: Kc Lai, Mf Yuen, Wong Bcy, Wm Wong, Fung Fmy, W. H. Wang, S. T. Yuen, Sy Leung, Km Chu, Hu Whc
    Abstract:

    Aim: To compare 1-week Ranitidine Bismuth Citrate-based (RBC) triple therapy vs. omeprazole-based (O) triple therapy for the eradication of Helicobacter pylori infection in Hong Kong with high prevalence of metronidazole resistance. Methods: Patients with non-ulcer dyspepsia and H. pylori infection were randomized to receive either: (i) RBCCM: Ranitidine Bismuth Citrate (pylorid) 400 mg, clarithromycin 250 mg and metronidazole 400 mg: or (ii) OCM: omeprazole 20 mg: clarithromycin 250 mg and metronidazole 400 mg. each given twice daily for 1 week. Endoscopy (CLO test, histology and culture) and 13C-urea breath test were performed before randomization and 6 weeks after drug treatment. Results: A total of 180 patients were randomized. H. pylori eradication rates (intention-to-treat. n = 180/per protocol, n = 166) were 83%/92% for RBCCM and 66%/70% for OCM (P = 0.01, intention-to-treat and P = 0.001, per protocol, respectively). RBCCM treatment was unaffected by metronidazole susceptibility and achieved a significantly higher eradication rate in metronidazole-resistant cases (89%) than the OCM group (45%, P = 0.0064). Conclusion: One-week Ranitidine Bismuth Citrate-based triple therapy is significantly better than omeprazole-based triple therapy for the eradication of H. pylori infection, especially in metronidazole-resistant cases. It is an effective regimen for the eradication of H. pylori infection in regions with a high prevalence of metronidazole resistance.link_to_subscribed_fulltex

Ej Van Der Wouden - One of the best experts on this subject based on the ideXlab platform.

  • The influence of metronidazole resistance on the efficacy of Ranitidine Bismuth Citrate triple therapy regimens for Helicobacter pylori infection
    Alimentary pharmacology & therapeutics, 1999
    Co-Authors: Ej Van Der Wouden, J. C. Thijs, Aa Van Zwet, A Kooy, Jan H. Kleibeuker
    Abstract:

    Aim : To assess the influence of metronidazole resistance on the efficacy of Ranitidine Bismuth Citrate-based triple therapy regimens in two consecutive studies. Methods : In the first study, patients with a culture-proven Helicobacter pylori infection were treated with Ranitidine Bismuth Citrate 400 mg, metronidazole 500 mg, and clarithromycin 500 mg, all twice daily for 1 week (RMC). In the second study, amoxycillin 1000 mg was substituted for clarithromycin (RMA). Susceptibility testing for metronidazole was performed with the E-test. Follow-up endoscopy was performed after ≥ 4 weeks. Antral biopsy samples were taken for histology and urease test, and culture and corpus samples for histology and culture. Results : 112 patients, 53 males, age 55 ± 14 years (39 duodenal ulcer, 7 gastric ulcer and 66 gastritis) were treated with RMC, and 89 patients, 52 males, age 58 ± 15 years (23 duodenal ulcer, 7 gastric ulcer and 59 gastritis) were treated with RMA. For RMC, intention-to-treat eradication results were 98% (59/60, 95% CI: 91–100%) and 95% (20/21, 95% CI: 76–100%) for metronidazole susceptible and resistant strains, respectively (P = 0.45). For RMA these figures were 87% (53/61, 95% CI: 76–94%) for metronidazole susceptible strains and 22% (2/9, 95% CI: 3–60%) for resistant strains (P = 0.0001). Conclusion : Both regimens are effective in metronidazole susceptible strains. However, in contrast to the amoxycillin-containing regimen, that containing clarithromycin is also effective in resistant strains.

  • One-Week Triple Therapy With Ranitidine Bismuth Citrate, Clarithromycin and Metronidazole Versus Two-Week Dual Therapy With Ranitidine Bismuth Citrate and Clarithromycin for Helicobacter pylori Infection: A Randomized, Clinical Trial
    The American journal of gastroenterology, 1998
    Co-Authors: Ej Van Der Wouden, J. C. Thijs, Aa Van Zwet, A Kooy, Jan H. Kleibeuker
    Abstract:

    One-Week Triple Therapy With Ranitidine Bismuth Citrate, Clarithromycin and Metronidazole Versus Two-Week Dual Therapy With Ranitidine Bismuth Citrate and Clarithromycin for Helicobacter pylori Infection: A Randomized, Clinical Trial